{
    "code": "52027066",
    "url": "https:\/\/info.fda.gov.tw\/MLMS\/H0001D.aspx?Type=Lic&LicId=52027066",
    "time": "2023-07-20 20:52:12",
    "許可證字號": "衛部藥輸字第027066號",
    "註銷狀態": "已註銷",
    "註銷日期": "112\/06\/02",
    "註銷理由": "有效期限已屆",
    "製造許可登錄編號": "",
    "有效日期": "111\/02\/22",
    "發證\/登錄日期": "106\/02\/22",
    "許可證\/登錄種類": "製　劑",
    "舊證字號": "",
    "醫療器材級數": "",
    "第一等級醫療器材原許可證字號": "",
    "第一等級醫療器材新登錄字號": "",
    "通關簽審文件編號": "DHA05202706601",
    "中文品名": "&quot;卡比&quot;倍莫舒癌注射劑100毫克",
    "英文品名": "Pemetrexed&quot;Kabi&quot; for Injection 100mg\/vial",
    "適應症": "1.併用cisplatin是治療局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）之第一線化療用藥。2.Pemetrexed單一藥物是局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）病人接受4個週期含鉑藥物的第一線化療後疾病並未惡化之維持療法。3.單一藥物是治療局部晚期或轉移性非小細胞肺癌（顯著鱗狀細胞組織型除外）之第二線治療用藥。4.與cisplatin併用於治療惡性肋膜間質細胞瘤。",
    "劑型": "243凍晶注射劑",
    "包裝": "100毫克玻璃小瓶裝 100支以下盒裝",
    "儲存溫度": "",
    "有效期間": "",
    "指示藥品審查基準": "",
    "標籤、仿單及包裝加註": "",
    "藥品類別": "05限由醫師使用",
    "管制藥品分類級別": "",
    "藥品分類": "",
    "監視期限": "",
    "主成分略述": "PEMETREXED DISODIUM HEPTAHYDRATE",
    "限制項目": "02輸　入 24監視期滿學名藥",
    "申請商名稱": "台灣費森尤斯卡比股份有限公司",
    "申請商地址": "台北市大安區仁愛路三段30號5樓32號5樓",
    "主製造廠": [
        {
            "製造廠名稱": "FRESENIUS KABI ONCOLOGY LIMITED",
            "製造廠廠址": "VILLAGE-KISHANPURA, P.O. GURU MAJRA, TEHSIL-NALAGARH, DISTT. SOLAN, (H.P.)-174101, INDIA",
            "製造廠公司地址": "",
            "製造廠國別": "INDIA",
            "製程": ""
        }
    ],
    "CCC號列": "",
    "藥理治療分類": "",
    "ingredients": [
        {
            "成分類別": "主成分",
            "成分代碼": "1004002410",
            "成分名稱": "PEMETREXED DISODIUM HEPTAHYDRATE",
            "含量描述": "Pemetrexed (as Pemetrexed Disodium) (Pemetrexed Disodium is formed in situ from Pemetrexed Diacid)",
            "含量": "100.0000000000",
            "單位": "MG"
        }
    ],
    "仿單外盒": [
        {
            "title": "Pemetrexed_FKT-027066(027347)-1120-110-08-17(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027066&Seq=004&Type=9"
        },
        {
            "title": "倍莫舒癌注射劑_標仿單擬稿_rev_20201105-109-11-05.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027066&Seq=003&Type=9"
        },
        {
            "title": "Pemetrexed 100_Label - Baddi-II - TWN-107-12-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027066&Seq=004&Type=8"
        },
        {
            "title": "Pemetrexed 100_Carton- Baddi-II - TWN-107-12-18(廠商自行上傳).pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027066&Seq=003&Type=8"
        },
        {
            "title": "衛部藥輸字第027066號_瓶標-106-06-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027066&Seq=002&Type=8"
        },
        {
            "title": "衛部藥輸字第027066號_外盒-106-06-08.pdf",
            "url": "https:\/\/www.fda.gov.tw\/MLMS\/ShowFile.aspx?LicId=52027066&Seq=001&Type=8"
        }
    ]
}